Table 3.
Reasons for patient preference at week 24 (efficacy set).
| Total (N = 60) |
Patients who preferred vildagliptin (n = 31) |
Patients who preferred liraglutide (n = 29) |
||||
|---|---|---|---|---|---|---|
| N | % | n | % | n | % | |
| How you take the medication (oral or injection) | ||||||
| Very unimportant | 5 | 8.3 | 1 | 3.2 | 4 | 13.8 |
| Unimportant | 15 | 25.0 | 5 | 16.1 | 10 | 34.5 |
| Undecided | 5 | 8.3 | 3 | 9.7 | 2 | 6.9 |
| Important | 22 | 36.7 | 11 | 35.5 | 11 | 37.9 |
| Very important | 13 | 21.7 | 11 | 35.5 | 2 | 6.9 |
| Side effects (nausea, vomiting and diarrhea) | ||||||
| Very unimportant | 4 | 6.7 | 1 | 3.2 | 3 | 10.3 |
| Unimportant | 13 | 21.7 | 5 | 16.1 | 8 | 27.6 |
| Undecided | 10 | 16.7 | 4 | 12.9 | 6 | 20.7 |
| Important | 15 | 25.0 | 7 | 22.6 | 8 | 27.6 |
| Very important | 18 | 30.0 | 14 | 45.2 | 4 | 13.8 |
| Blood sugar lowering | ||||||
| Very unimportant | 3 | 5.0 | 1 | 3.2 | 2 | 6.9 |
| Unimportant | 8 | 13.3 | 3 | 9.7 | 5 | 17.2 |
| Undecided | 3 | 5.0 | 3 | 9.7 | 0 | 0.0 |
| Important | 9 | 15.0 | 7 | 22.6 | 2 | 6.9 |
| Very important | 37 | 61.7 | 17 | 54.8 | 20 | 69.0 |
| Other effects (weight loss and blood pressure decrease) | ||||||
| Very unimportant | 2 | 3.3 | 0 | 0.0 | 2 | 6.9 |
| Unimportant | 10 | 16.7 | 6 | 19.4 | 4 | 13.8 |
| Undecided | 9 | 15.0 | 5 | 16.1 | 4 | 13.8 |
| Important | 18 | 30.0 | 10 | 32.3 | 8 | 27.6 |
| Very important | 21 | 35.0 | 10 | 32.3 | 11 | 37.9 |
Efficacy set consisted of all patients who completed the patient preference questionnaire at the end of the study.